An Official Website of the United States Government
Preclinical development of novel small molecule malaria drugs that overcome drug
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2011Title: Preclinical development of novel small molecule malaria drugs that overcome drugAgency: HHSContract: 1R41AI094959-01Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to overcome drug resistance. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. A small set of carefully-selectedcandidates will be advanced through preclinical testing, leading to the selection of a single drug for a pre-Investigational New Drug meeting with the Food and Drug Administration. With guidance from the Food and Drug Administration, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys in phase II of this work. The overall goal will be completion of preclinical studies leading to approval of the Investigative New Drug (IND) application for a drug to be used in a Phase-1 human clinical trial. PUBLIC HEALTH RELEVANCE: Malaria is a disease that infects about half a billion people annually, and kills nearly one million, most of whom are children or pregnant women. The impact of malaria is increasing, partly because the parasite that causes malaria has evolved into strains that are resistant to the best current drugs for treating the disease. This project involves preclinical evaluation of novel drugs designed to circumvent this resistance, paving the way toward approval for human clinical trials. The drug candidates show promising results in early studies, and are designed to be inexpensive as well as safe for all target groups, including pregnant women and children.Small Business Information at Submission:Research Institution Information:DESIGNMEDIX, INC.
2828 Corbett Ave Suite 140A PORTLAND, OR -EIN/Tax ID: 126277928DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: NoPORTLAND STATE UNIVERSITY
PORTLAND STATE UNIVERSITY
BOX 751
PORTLAND, OR 97207-Contact:
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: |
Program Year/Program: 2011 / STTR |
|
Agency Tracking Number: R41AI094959 |
Solicitation Year: 2011 |
Solicitation Topic Code: NIAID |
Solicitation Number: PA10-124 |